08:00 , Mar 7, 2016 |  BC Week In Review  |  Company News

Alba, Innovate Biopharmaceuticals deal

Innovate gained an exclusive, worldwide license to Alba’s larazotide acetate ( INN-202). Alba will receive an undisclosed upfront payment and is eligible for undisclosed milestones. INN-202 is in Phase IIb testing to treat celiac disease....
02:08 , Feb 7, 2015 |  BC Extra  |  Financial News

Poxel raises EUR 26.8M in IPO, private placement

Poxel S.A. (Euronext:POXEL) gained EUR 0.53 to EUR 7.19 on Friday -- its first trading day after raising EUR 26.8 million ($30.4 million) in an IPO and concurrent private placement. Poxel raised EUR 3.6 million...
08:00 , Jan 29, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Two-component response regulator WalR (walR)

Infectious disease INDICATION: Gram-positive bacterial infection Cell culture studies suggest the Streptomonospora alba-derived antimicrobial peptide streptomonomicin could help treat Gram-positive bacterial infections. In vitro, streptomonomicin killed multiple species of Gram-positive bacteria including Bacillus anthracis and Listeria monocytogenes...
08:00 , Nov 13, 2014 |  BC Innovations  |  Cover Story

Boosting adjuvants

For all the talk of new vaccines, not much attention has been paid to the need for better adjuvants, which have remained stuck on alum-based products for decades. The NIH is committing up to $70...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

Larazotide: Phase IIb data

The double-blind, North American Phase IIb CLIN1001-012 trial in 342 celiac disease patients who have persistent symptoms despite being on a gluten-free diet showed that thrice-daily oral larazotide met the primary endpoint of improving the...
01:58 , Feb 12, 2014 |  BC Extra  |  Clinical News

Alba celiac compound meets in Phase IIb trial

Alba Therapeutics Corp. (Baltimore, Md.) said thrice-daily oral larazotide ( AT-1001) met the primary endpoint in the Phase IIb CLIN1001-012 trial to treat celiac disease. Larazotide improved the celiac disease domains of the gastrointestinal symptoms...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

Alba management update

Alba Therapeutics Corp., Baltimore, Md.   Business: Autoimmune, Inflammation, Endocrine/Metabolic   Transitioned: Wendy Perrow to CEO and a director from president and COO   ...
07:00 , Oct 7, 2013 |  BioCentury  |  Strategy

Room for improvement

AbbVie Inc. has struck two deals for compounds that would compete with marketed products against the same targets, banking that partners Ablynx N.V. and Galapagos N.V. will be able to show their compounds produce better...
07:00 , May 7, 2012 |  BC Week In Review  |  Clinical News

Larazotide: Phase IIb started

Alba began the double-blind, placebo-controlled, North American Phase IIb CLIN1001-012 trial to evaluate thrice-daily 0.5, 1 and 2 mg larazotide in about 320 patients with celiac disease who have persistent symptoms despite being on a...
07:00 , Mar 26, 2012 |  BioCentury  |  Emerging Company Profile

ImmusanT: Having their cake

ImmusanT Inc. is developing what could be the first treatment for celiac disease that allows patients to eat a normal diet. The company's Nexvax2 vaccine seeks to reprogram CD4+ T cells to induce gluten tolerance. The...